Compare HZO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | CGEM |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United States |
| Employees | 3385 | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 769.2M | 904.7M |
| IPO Year | 1998 | 2020 |
| Metric | HZO | CGEM |
|---|---|---|
| Price | $35.05 | $13.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $30.00 | ★ $30.13 |
| AVG Volume (30 Days) | 336.6K | ★ 881.8K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,309,288,000.00 | N/A |
| Revenue This Year | $3.67 | N/A |
| Revenue Next Year | $4.01 | $5.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.52 | $5.68 |
| 52 Week High | $34.68 | $16.74 |
| Indicator | HZO | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 42.75 |
| Support Level | $24.00 | $12.41 |
| Resistance Level | N/A | $16.21 |
| Average True Range (ATR) | 1.71 | 0.94 |
| MACD | 0.13 | -0.16 |
| Stochastic Oscillator | 84.13 | 11.57 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.